10-Q · May 15, 2026
For Q4 2026, Scienture Holdings, Inc. reported a revenue of $56,325, marking a significant increase of 449% compared to $10,258 in Q4 2025. The gross profit rose to $53,850, reflecting a turnaround from previous…
Earnings analysis · 10-Q
SCNX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include the financial statements or MD&A, so current-quarter revenue, margins, EPS, cash flow, balance-sheet trends and segment performance cannot be assessed. Controls were deemed…
Read full summary
The provided 10-Q extract does not include the financial statements or MD&A, so current-quarter revenue, margins, EPS, cash flow, balance-sheet trends and segment performance cannot be assessed. Controls were deemed effective as of June 30, 2026, with no material control changes reported. The principal disclosed concerns are potential dilution from 433,331 shares issued to executives, a 150,000-share insider sales plan, secured financing arrangements dated April 27, 2026, and inherently uncertain litigation outcomes.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Rated Effective
Management concluded that disclosure controls were effective as of June 30, 2026, providing reasonable assurance that required information was reported within SEC-prescribed time periods.
-
Executive-Related Equity Issuance
The company issued 433,331 shares of common stock to certain executive officers for services during the three months ended June 30, 2026.
-
No Material Control Changes
No changes in internal control over financial reporting during the quarter ended June 30, 2026 materially affected, or were reasonably likely to materially affect, those controls.
-
Insider Sales Plan Disclosed
The executive chairman and co-CEO adopted a Rule 10b5-1 sales plan on June 3, 2026, allowing sales of up to 150,000 shares beginning November 2, 2026, at no less than $1.00 per share.
What to watch
-
No Risk-Factor Update
The company disclosed 0 material changes to the risk factors previously reported in its Form 10-K filed March 30, 2026, and amended April 30, 2026; the filing therefore provides no evidence of risk-factor improvement.
-
Equity Dilution and Selling Pressure
Potential dilution and selling pressure are risks from the 433,331 shares issued to executive officers and the separate plan authorizing sales of up to 150,000 shares beginning November 2, 2026.
-
Secured Financing Obligations
The company has secured financing documents dated April 27, 2026, including a secured promissory note, security agreements, intellectual-property security agreement, pledge agreement and guaranty, indicating lender claims over company assets and intellectual property.
-
Uncertain Litigation Outcomes
Litigation outcomes remain inherently uncertain; the company states that an adverse resolution in excess of management expectations could materially adversely affect results for that reporting period, although it currently expects 0 material adverse effect from pending matters individually or in the aggregate.
Management's outlook
The provided 10-Q extract does not contain quantitative revenue or EPS guidance, and no explicit outlook was disclosed.
Earlier filings 2
10-K · April 30, 2026
Scienture Holdings experienced significant volatility in its financial performance over the past year, primarily driven by its transition towards a focused specialty pharmaceutical business. Management's strategy…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.